Sociedad Americana de Hirudoterapia

Transcriptomics and differential gene expression in Helobdella: contrasting feeding and fasting modes

Transcriptomics study published in Ecology and Evolution (2019)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenómica y proteómicaKhan MS · Ecology and evolution, 2019

Abstract

The medicinal utility of leeches has been demonstrated through decades of use in modern hospital settings, mainly as relievers of venous congestion following flap or digit replantation surgery. In the present study, we sequence and annotate (through BLAST- and Gene Ontology-based approaches) the salivary transcriptome of the nonblood feeding hirudinid Whitmania pigra and assess the differential gene expression of anticoagulation factors (through both quantitative real-time PCR [qRT-PCR] and in silico-based methods) during feeding and fasting conditions. This was done in order to evince the diversity of putative anticoagulation factors, as well as estimate the levels of upregulation of genes immediately after feeding. In total, we found sequences with demonstrated orthology (via both phylogenetic analyses and BLAST-based approaches) to seven different proteins that have previously been linked to anticoagulatory capabilities-eglin C, bdellin, granulin, guamerin, hyaluronidase, destabilase I, and lipocalin. All of these were recovered from leeches both in the fasting and in the feeding conditions, but all show signs of upregulation in the feeding leeches. Interestingly, our RNA-seq effort, coupled with a hypergeometric test, indicated that the differentially expressed genes were disproportionately involved in three main immunological pathways (endocytosis, peroxisome regulation, and lysosome regulation). The results and implications of the finding of anticoagulants in this nonblood feeding leech and the putative upregulation of anticoagulation factors after feeding are briefly discussed in an evolutionary context.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Compares fed vs fasted Helobdella transcriptomes, identifying genes upregulated during digestion of blood meal — informs leech metabolic biology.

Por qué esto importa para la hirudoterapia

This study sequenced and annotated the salivary transcriptome of the nonblood-feeding hirudinid leech Whitmania pigra and assessed differential expression of anticoagulation-associated genes during feeding versus fasting using RNA-seq and qRT-PCR. It recovered sequences with orthology to seven known anticoagulant or anticoagulant-linked proteins (eglin C, bdellin, granulin, guamerin, hyaluronidase, destabilase I, lipocalin), all upregulated in feeding animals, and found that differentially expressed genes were enriched in immunological pathways (endocytosis, peroxisome regulation, lysosome regulation). This is relevant to ASH because it expands understanding of the diversity and regulation of putative anticoagulant factors within the leech salivary repertoire, even in a non-sanguivorous species, offering evolutionary context for the leech secretome. The study is purely molecular/transcriptomic with no functional protein assays, clinical data, or direct hirudotherapy application; Whitmania pigra is not a standard medicinal leech.

Citación

Transcriptomics and differential gene expression in Helobdella: contrasting feeding and fasting modes.

Khan MS · Ecology and evolution, 2019

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.